Drug intelligence / Profile preview

atomoxetine + coenzyme Q10

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of atomoxetine, a selective norepinephrine reuptake inhibitor (NRI), and coenzyme Q10, an antioxidant supplement. This combination has been studied for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), particularly in patients who have not fully responded to atomoxetine alone. The addition of coenzyme Q10 to atomoxetine has shown improved ADHD symptoms, especially hyperactivity, impulsivity, and learning problems, with minimal additional adverse effects.

Other names: atomoxetine + ubiquinoneatomoxetine + CoQ10

Targets

NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)ND1 (Mitochondrial electron transport chain complex I)

Beyond the preview

Go deeper on atomoxetine + coenzyme Q10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atomoxetine + coenzyme Q10.

Explore the full profile